Recently, a comprehensive cohort study utilizing data from the Korean National Health Insurance Service from 2004 to 2021 indicated no significant correlation between GLP-1 RAs and the incidence of new-onset malignancies, with a median follow-up of 8 years [109]
GLP-1 medications, like Ozempic and Wegovy, have shown promising results for weight loss and metabolic health
While both Semaglutide GLP-1 and Liraglutide have been proven effective, current evidence suggests that Semaglutide GLP-1 maybe even more effective
AstraZenecas $2 billion licensing deal with Eccogene for an experimental pill offers fewer side effects based on early trials
Declare these items to the officer at the checkpoint
(See Figure 2 for a timeline of key activities associated with the GLP-1 coverage demonstrations.) Medicare coverage of GLP-1s for obesity begins in July 2026 through the Medicare GLP-1 Bridge and will be extended through the end of 2027 CMS will provide Part D beneficiaries with coverage of select GLP-1s for obesity from July 1, 2026 to December 31, 2027 (originally December 31, 2026) through the Medicare GLP-1 Bridge, which is a short-term demonstration established using Section 402 demonstration authority
